GLP-1 and Thyroid Cancer Risk: What the Data Actually Shows

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

While initial animal studies and an FDA warning raised concerns about GLP-1 receptor agonists and medullary thyroid carcinoma (MTC), large-scale human data generally do not show an increased risk for common thyroid cancers. The primary concern remains with MTC, particularly in patients with pre-existing risk factors, necessitating careful patient selection and monitoring.

GLP-1 and Thyroid Cancer Risk: What the Data Actually Shows

The introduction of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) has revolutionized the management of type 2 diabetes and obesity. However, like any powerful medication, their widespread use has prompted scrutiny regarding potential side effects, with thyroid cancer risk being a notable concern. This isn't a simple "yes or no" answer; understanding the data requires distinguishing between different types of thyroid cancer and interpreting the evidence from both preclinical and human studies.

The initial concern stemmed from rodent studies, where GLP-1 RAs were found to cause dose-dependent and treatment duration-dependent thyroid C-cell tumors (which can lead to medullary thyroid carcinoma, MTC) in rats and mice. This led the FDA to issue a black box warning for GLP-1 RAs, advising against their use in patients with a personal or family history of MTC or in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It's crucial to understand that this warning is primarily based on these animal findings, and MTC is a rare form of thyroid cancer, accounting for only about 1-2% of all thyroid cancers.

However, when we look at large-scale human observational studies and meta-analyses, the picture becomes more reassuring for the vast majority of patients. Numerous studies, some involving hundreds of thousands of patients, have investigated the association between GLP-1 RA use and the risk of thyroid cancer. For instance, a comprehensive study published in JAMA Otolaryngology in 2025 by Brito et al. found that GLP-1 RA initiation was associated with a new diagnosis of thyroid cancer only in the short term, suggesting a potential detection bias rather than a causal link. This means that patients starting these medications might undergo more frequent medical evaluations, leading to earlier detection of pre-existing conditions.

Similarly, a meta-analysis by Vilsbøll et al. (2025) concluded that the totality of data did not suggest an association between liraglutide or semaglutide use and thyroid cancer risk in adults. Another large study published in the BMJ in 2024 found no substantially increased risk of thyroid cancer over a mean follow-up of 3.9 years with GLP-1 RA use. These findings are critical because they reflect real-world clinical practice and involve diverse patient populations, providing a more accurate assessment of risk than animal models alone.

Despite these reassuring findings for common thyroid cancers (papillary, follicular), the concern for medullary thyroid carcinoma (MTC) persists, particularly for individuals with pre-existing risk factors. The FDA warning remains in place, and clinicians are advised to screen patients for a history of MTC or MEN 2 before initiating GLP-1 RA therapy. Unlike other thyroid cancers, MTC originates from parafollicular C-cells, which express GLP-1 receptors, making them theoretically susceptible to GLP-1 RA stimulation. However, the physiological relevance of this in humans, especially at therapeutic doses, is still debated.

Some studies have shown a modest increase in the relative risk of thyroid cancer with GLP-1 RA use, particularly after 1-3 years of exposure, as noted in a 2022 study in Diabetes Care. However, these findings often come with caveats, such as small absolute risk increases and potential confounding factors. It's important to differentiate between a statistically significant relative risk and a clinically significant absolute risk. Even if a relative risk is elevated, if the baseline incidence of the disease is very low (as with MTC), the absolute increase in risk for an individual patient remains minimal.

The practical takeaway is that for the vast majority of patients without a personal or family history of MTC or MEN 2, the benefits of GLP-1 RAs in managing diabetes and obesity generally outweigh the theoretical risk of thyroid cancer. Don't let the black box warning overshadow the extensive human data that largely refutes a widespread causal link for common thyroid cancers. However, always ensure a thorough medical history is taken, and if you have any concerns or develop symptoms like a neck mass or difficulty swallowing, discuss them with your healthcare provider. Vigilance and informed decision-making, rather than alarm, should guide the use of these important medications.